Trials
MRD trials
The curated index is a sourced list of studies. Accruing is the live ClinicalTrials.gov set of studies that are recruiting or not yet recruiting. DYNAMIC-III is not in the curated index because it is registered in Australia and New Zealand, not with an NCT id.
Recruiting and not-yet-recruiting studies that use ctDNA, cfDNA, or MRD in eligibility, a treatment decision, or a primary or secondary endpoint, plus observational studies focused on that testing. 1123 studies from 2267 registry records. Hematologic trials that list MRD only as a secondary endpoint are listed separately. Last synced Nov 18, 2026, 2:04 PM EST.
Lenvatinib Plus Chemotherapy for pNET Liver Metastases
Peking Union Medical College Hospital · 1 locations · Updated 2026-09-23
Utility of ctDNA in Early Switch of First-line Chemotherapy in Metastatic Pancreatic Ductal Adenocarcinoma
University of Miami · 1 locations · Updated 2026-09-21
Investigational Scan (68Ga-FAPI-46 PET/CT) for Imaging of Cancer-Associated Fibroblasts for Localized Pancreatic Ductal Adenocarcinoma
Mayo Clinic · 1 locations · Updated 2026-08-10
Metronomic Capecitabine, Oxaliplatin and UGT1A1 Genotype-directed Irinotecan in Metastatic Pancreatic Cancer Patients
National Cancer Centre, Singapore · 1 locations · Updated 2026-06-23
KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · 1 locations · Updated 2026-04-15
Phase I/II Study: Allogeneic NK-cell Therapy With Chemotherapy for Post-Surgery PDA or Cholangiocarcinoma Patients
Medigen Biotechnology Corporation · 1 locations · Updated 2025-12-17
Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI
UNICANCER · 22 locations · Updated 2025-12-02
Neoadjuvant/Adjuvant Sintilimab, Nab-paclitaxel, and Gemcitabine for Resectable/Borderline Resectable Pancreatic Cancer
Shanghai Zhongshan Hospital · 1 locations · Updated 2025-01-22
ctDNA Assay in Patients With Resectable Pancreatic Cancer
University of Oklahoma · 2 locations · Updated 2026-10-27
Hepatic Artery Infusion Pump Chemotherapy for Liver Metastases From Resected Pancreatic and Duodenal Adenocarcinoma
AdventHealth · 1 locations · Updated 2026-09-29
Using Tumour DNA and Proteins to Better Understand How Pancreatic Cancer Responds to Treatment
British Columbia Cancer Agency · 1 locations · Updated 2026-09-16
Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers
University of California, Irvine · 1 locations · Updated 2026-08-31
ctDNA Monitoring After Pancreatic Cancer Surgery (K-4CARE Lite Study)
Chang Gung Memorial Hospital · 1 locations · Updated 2026-08-03
Determining Minimal Residual Disease Using ctDNA Deep Sequencing
Masaryk Memorial Cancer Institute · 1 locations · Updated 2026-06-24
Evaluating the Prognostic Capability of ctDNA as a Biomarker in Pancreatic Cancer Patients Undergoing Neoadjuvant Chemotherapy
Northwestern University · 3 locations · Updated 2026-06-18
The Canopy Cancer Collective Clinical Registry Protocol
Canopy Cancer Collective, LLC · 10 locations · Updated 2026-05-26
Prediction of Peritoneal Dissemination of Digestive Tumors Through the Study of Circulating Tumor DNA
Assistance Publique - Hôpitaux de Paris · Locations not reported · Updated 2026-05-08
A Registry to Capture Patient Outcomes With KRAS G12R Altered Advanced Pancreatic Ductal Adenocarcinoma Treated With MEK Inhibitor-based Combination Therapy
Mandana Kamgar, MD · 1 locations · Updated 2026-05-05
Implementing ctDNA and Circular DNA in Patients With Localized Pancreatic Cancer
Copenhagen University Hospital at Herlev · 5 locations · Updated 2026-03-27
XH001 Combination With Immunocheckpoint Inhibitor and Chemotherapy for Patients With Resected Pancreatic Cancer
Wu Wenming · 1 locations · Updated 2026-02-13
Study of KRAS-Specific Vaccine in Patients With KRAS-Mutated Solid Tumors
Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Locations not reported · Updated 2026-02-09
Use of Ctdna in Patients With Gastrointestinal Tract Tumors
Fondazione Policlinico Universitario Agostino Gemelli IRCCS · 1 locations · Updated 2025-09-02
A Cohort Study on ctDNA MRD in Neoadjuvant Therapy for Pancreatic Cancer
Ruijin Hospital · 2 locations · Updated 2025-07-29
Adjuvant Pancreatic Therapy Guided by MRD
Ruijin Hospital · 1 locations · Updated 2025-07-15
French Assessment of MRD by Liquid Biopsies in PDAC Patients (FRENCH.MRD.PDAC)
University Hospital, Montpellier · 1 locations · Updated 2025-07-10
CtDNA-guided Maintenance Therapy in Pancreatic Cancer
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · 1 locations · Updated 2025-07-08
MSCAN: ctDNA Methylation as Prognostic and Theranostic Tool for Pancreatic Cancer
Yingbin Liu, MD, PhD, FACS · 1 locations · Updated 2025-07-01
Prospective Cohort of Patients Treated Using Neoadjuvant Modified FOLFIRINOX 6 Cycles for Potentially Resectable Pancreatic Duct Adenocarcinoma, Candidate for Participation in the PANACHE02 Clinical Trial
University Hospital, Rouen · 1 locations · Updated 2025-06-24
Evaluate the Clinical Feasibility of a Novel Neoantigen-Reactive CD8+ T Cell (NART) Detection Technology for Postoperative MRD Surveillance of Pancreatic Cancer
Shanghai Zhongshan Hospital · 1 locations · Updated 2025-04-24
Prediction of Surgical Resectability After FOLFIRINOX Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Cancer: the Role of Diffusion Weighted Magnetic Resonance Imaging, Radiomics and Liquid Biopsy (PeRFormanCe Trial)
University Hospital, Ghent · 8 locations · Updated 2025-04-02
Construction of Molecular Diagnostic Marker Model for Pancreatic Cystic Tumors Based on Pancreatic Cystic Fluid Samples
Zhaoshen Li · 1 locations · Updated 2025-02-11
Early-stage Detection of LIver, Biliary TRAct and PancReatic Cancers
Second Affiliated Hospital, Zhejiang University, School of Medicine · 1 locations · Updated 2025-02-10
The Influence of Secretin Stimulated Pancreatic Secretion on ctDNA Expression in Patients With Pancreatic Ductal Adenocarcinoma: The Role of Biomarkers in Determining the Prognosis of Pancreatic Ductal Adenocarcinoma
Charles University, Czech Republic · 1 locations · Updated 2025-02-04
Multicenter Study of Circulating Tumor DNA in Patients With Pancreatic Cancer Using a Personalized Panel
Invitae Corporation · 1 locations · Updated 2023-09-21
AssesSment of Early-deteCtion basEd oN liquiD Biopsy in PANCEATIC Cancer (ASCEND-PANCREATIC)
Ruijin Hospital · 3 locations · Updated 2023-05-06
Status can change after this sync. The curated list is the other view on this page. Evidence holds the published results.